Department of Surgery, Section of Gynecology, Faculdade de Medicina, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil.
Rev Bras Ginecol Obstet. 2022 Jan;44(1):25-31. doi: 10.1055/s-0041-1741410. Epub 2022 Jan 29.
The present study aimed to understand patient perception of the adverse effects of contraceptives to improve health care and adherence to treatment.
An online questionnaire was available for women in Brazil to respond to assess their perception of adverse effects and their relationship with contraceptive methods.
Of all 536 women who responded, 346 (64.6%) reported current contraceptive use. One hundred and twenty-two (122-34.8%) women reported having already stopped using contraception because of the adverse effects. As for the contraceptive method used, the most frequent was the combined oral contraceptive (212-39.6%). When we calculated the relative risk for headache, there was a relative risk of 2.1282 (1.3425-3.3739; 95% CI), suggesting that the use of pills increases the risk of headache, as well as edema, in which a relative risk of 1.4435 (1.0177-2.0474; 95% CI) was observed. For low libido, the use of oral hormonal contraceptives was also shown to be a risk factor since its relative risk was 1.8805 (1.3527-2.6142; 95% CI). As for acne, the use of hormonal contraceptives proved to be a protective factor, with a relative risk of 0.3015 (0.1789-0.5082; 95% CI).
The choice of a contraceptive method must always be individualized, and the patients must be equal participants in the process knowing the expected benefits and harms of each method and hormone, when present.
本研究旨在了解患者对避孕药具不良反应的认知,以改善医疗保健和治疗依从性。
巴西的女性可以在线回答问卷,以评估她们对不良反应的认知及其与避孕方法的关系。
在所有 536 名回应的女性中,346 名(64.6%)报告正在使用避孕药具。122 名(122-34.8%)女性因不良反应而停止使用避孕药具。就所使用的避孕方法而言,最常见的是复方口服避孕药(212-39.6%)。当我们计算头痛的相对风险时,发现使用避孕药具会增加头痛的风险,相对风险为 2.1282(1.3425-3.3739;95%置信区间),以及水肿,相对风险为 1.4435(1.0177-2.0474;95%置信区间)。对于性欲低下,口服激素避孕药的使用也被证明是一个风险因素,因为其相对风险为 1.8805(1.3527-2.6142;95%置信区间)。对于痤疮,激素避孕药的使用被证明是一个保护因素,相对风险为 0.3015(0.1789-0.5082;95%置信区间)。
避孕方法的选择必须始终个体化,患者必须平等参与到了解每种方法和激素的预期获益和危害的过程中。